This is a Phase 1 and Phase 2 study to evaluate the safety and antitumor activity of INV-9956 in adult patients with advanced metastatic Castration Resistant Prostate Cancer.
Written informed consent obtained.
Male aged ≥ 18 years.
Histologically confirmed adenocarcinoma of the prostate.
Castration resistant prostate cancer with serum testosterone <50 ng/dL.
Have a medical condition such as Crohn's disease or have undergone significant surgery to the gastrointestinal tract that could impair absorption or that could result in short bowel syndrome with diarrhea due to malabsorption.
History of pituitary or adrenal dysfunction.
Poorly controlled diabetes mellitus.
Clinically significant abnormality in serum potassium and sodium.
8
Treatment groupsSee each treatment group below.